This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Thursday's Health Winners & Losers

Shares of Encysive Pharmaceuticals (ENCY) were among the best-performing health-related stocks Thursday, jumping 15% after the company submitted a complete response to the Food and Drug Administration for its pulmonary arterial hypertension drug.

"Encysive and the FDA have come to a mutual agreement that the company's approach to responding to the items outlined in the approvable letter with our existing data set is reasonable, making possible the submission of a complete response," the company said.

In March, shares in Encysive were hammered after the company received an approvable letter from the FDA requesting more information about the drug Thelin. The company said it expects to hear within 30 days whether the FDA will accept its latest submission for review. Shares were trading up 57 cents to $4.39.

Shares of Angiotech Pharmaceuticals (ANPI) rose 2% after the medical-device company narrowed its 2006 earnings forecast and announced an acquisition. The company now sees full-year adjusted earnings of 79 cents to 81 cents a share. Previously, the company forecast a profit of 76 cents to 81 cents a share. Angiotech predicts revenue of $325 million to $335 million. The updated guidance is better than the earnings of 78 cents a share and revenue of $312 million that analysts project.

For 2007, Angiotech anticipates adjusted earnings of 90 cents to 95 cents a share on revenue of $400 million to $425 million. Analysts project earnings of $1 a share on revenue of $400.7 million.

Separately, Angiotech said it signed a definitive agreement to buy privately held Quill Medical for $40 million. Quill makes aesthetic surgery and wound-closure products. The deal is expected to close in the third quarter. Angiotech shares recently changed hands at $13.97, up 24 cents.

Shares of United Natural Foods (UNFI - Get Report) jumped 9% after the distributor of natural and organic foods posted third-quarter results that topped forecasts. For the quarter ended April 30, the company earned $12.3 million, or 29 cents a share, up from $10.7 million, or 26 cents a share, a year earlier. Sales rose to $637.1 million from $534.3 million. Analysts polled by Thomson First Call expected earnings of 28 cents a share on sales of $622 million. "These results reflect the continued strong consumer demand for natural and organic products as well as the underlying strength of our sales channels across all regions in the country," the company said.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
PDCO $50.43 0.33%
UNH $115.01 1.00%
TEVA $56.56 -0.01%
UNFI $81.32 -0.50%
AAPL $126.60 -1.50%


DOW 18,133.66 +36.76 0.20%
S&P 500 2,099.60 +1.07 0.05%
NASDAQ 4,977.6470 +10.5060 0.21%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs